Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...
Schematic representation of histone-modifying factor recruitment on cccDNA minichromosomes in relation to viral protein HBx. In the presence of HBx, histone-modifying factors such as p300/CBP, Set1A, ...
- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of ...
Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming ...
Some 254 million people live with a chronic hepatitis B (HBV) infection that is often asymptomatic for decades, only to emerge in an advanced stage of disease that turns to fatal cirrhosis or liver ...
PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...
As part of their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) can establish an infection in liver cells, researchers led by teams at Memorial Sloan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results